title: The human insulin analogue aspart is not the almighty solution for insulin allergy.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Takata
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Kumon
authors.forename: Fumiaki
authors.initials: F
authors.lastname: Osaki
authors.forename: Chizuru
authors.initials: C
authors.lastname: Kumagai
authors.forename: Kaoru
authors.initials: K
authors.lastname: Arii
authors.forename: Yukio
authors.initials: Y
authors.lastname: Ikeda
authors.forename: Tadashi
authors.initials: T
authors.lastname: Suehiro
authors.forename: Kozo
authors.initials: K
authors.lastname: Hashimoto
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000276:immunology*; D004342:Drug Hypersensitivity / Q000175:diagnosis* / Q000517:prevention & control; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D007328:Insulin / Q000009:adverse effects* / Q000031:analogs & derivatives; D061267:Insulin Aspart; D008875:Middle Aged
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D061267:Insulin Aspart